Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308976884> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4308976884 endingPage "vii107" @default.
- W4308976884 startingPage "vii106" @default.
- W4308976884 abstract "Abstract Diffuse invasion is a hall mark of glioblastoma (GB) and one of the primary causes of poor clinical outcomes in GBM patients. Tumor cells migrate deep into the normal brain tissues are frequently protected by the BBB, making them particularly difficult to treat. New therapeutic targets are needed. Our previous studies using spatially dissected and functionally validated matching pairs of invasive and tumor core GBM cells identified KCNA1 as a shared gene that is selectively over-expressed in the invasive GBM cells in 6 patient derived orthotopic xenograft (PDOX) mouse models of pediatric GBM (Huang YL et al, Adv Science 2021). A subsequent analysis of adult GBM RNAseq data from IVY Atlas revealed a significantly elevated expression of KCNA1 (4.9 fold) in the invasive edges of patient GBM tumors. It is also one of the 11 core molecules identified in GEO and TCGA databases through an integrated bioinformatic analysis (Yang J, Front Onc 2021). To determine the anti-invasive activities of targeting KCNA1, we treated three highly invasive adult GBM PDOX models with 4-aminopyridine (4-AP), an old lipid soluble drug that easily penetrate the BBB, at 5 mg/kg, i.p., 5 days/week for 8 weeks acing alone or in combination with fractionated radiation (at 2 Gy/day x days). As single agent, 4-AP significantly extended median animal survival times in 1/3 GBM models (69 to 77 days, P = 0.033). Combination with XRT did not significantly improve the animal survival times in the three models. Systematic analysis of GBM invasion in mouse brains of the 3 PDOX models before, during and after 4-AP treatment revealed remarkable inhibition of tumor invasion. Our data highlighted the role of KCNA1 in promoting GBM invasion and support the fine tuning of 4-AP dose, schedule, and length of treatment to serve as a novel component of anti-GBM invasion therapies." @default.
- W4308976884 created "2022-11-20" @default.
- W4308976884 creator A5001660190 @default.
- W4308976884 creator A5026418876 @default.
- W4308976884 creator A5029272808 @default.
- W4308976884 creator A5035570068 @default.
- W4308976884 creator A5042271162 @default.
- W4308976884 creator A5054728664 @default.
- W4308976884 creator A5058965019 @default.
- W4308976884 creator A5081541074 @default.
- W4308976884 creator A5088934759 @default.
- W4308976884 date "2022-11-01" @default.
- W4308976884 modified "2023-09-28" @default.
- W4308976884 title "DDDR-35. TARGETING GBM INVASION BY INHIBITING KCNA1 WITH 4-AMINOPYRIDINE: AN FDA APPROVED DRUG THAT EASILY PASS THROUGH THE BBB" @default.
- W4308976884 doi "https://doi.org/10.1093/neuonc/noac209.400" @default.
- W4308976884 hasPublicationYear "2022" @default.
- W4308976884 type Work @default.
- W4308976884 citedByCount "0" @default.
- W4308976884 crossrefType "journal-article" @default.
- W4308976884 hasAuthorship W4308976884A5001660190 @default.
- W4308976884 hasAuthorship W4308976884A5026418876 @default.
- W4308976884 hasAuthorship W4308976884A5029272808 @default.
- W4308976884 hasAuthorship W4308976884A5035570068 @default.
- W4308976884 hasAuthorship W4308976884A5042271162 @default.
- W4308976884 hasAuthorship W4308976884A5054728664 @default.
- W4308976884 hasAuthorship W4308976884A5058965019 @default.
- W4308976884 hasAuthorship W4308976884A5081541074 @default.
- W4308976884 hasAuthorship W4308976884A5088934759 @default.
- W4308976884 hasBestOaLocation W43089768841 @default.
- W4308976884 hasConcept C126322002 @default.
- W4308976884 hasConcept C142724271 @default.
- W4308976884 hasConcept C143998085 @default.
- W4308976884 hasConcept C2776194525 @default.
- W4308976884 hasConcept C2780035454 @default.
- W4308976884 hasConcept C2780922449 @default.
- W4308976884 hasConcept C502942594 @default.
- W4308976884 hasConcept C71924100 @default.
- W4308976884 hasConcept C83743174 @default.
- W4308976884 hasConcept C98274493 @default.
- W4308976884 hasConceptScore W4308976884C126322002 @default.
- W4308976884 hasConceptScore W4308976884C142724271 @default.
- W4308976884 hasConceptScore W4308976884C143998085 @default.
- W4308976884 hasConceptScore W4308976884C2776194525 @default.
- W4308976884 hasConceptScore W4308976884C2780035454 @default.
- W4308976884 hasConceptScore W4308976884C2780922449 @default.
- W4308976884 hasConceptScore W4308976884C502942594 @default.
- W4308976884 hasConceptScore W4308976884C71924100 @default.
- W4308976884 hasConceptScore W4308976884C83743174 @default.
- W4308976884 hasConceptScore W4308976884C98274493 @default.
- W4308976884 hasIssue "Supplement_7" @default.
- W4308976884 hasLocation W43089768841 @default.
- W4308976884 hasOpenAccess W4308976884 @default.
- W4308976884 hasPrimaryLocation W43089768841 @default.
- W4308976884 hasRelatedWork W1480012785 @default.
- W4308976884 hasRelatedWork W1983544050 @default.
- W4308976884 hasRelatedWork W2030471898 @default.
- W4308976884 hasRelatedWork W2125138090 @default.
- W4308976884 hasRelatedWork W2130549011 @default.
- W4308976884 hasRelatedWork W2141845144 @default.
- W4308976884 hasRelatedWork W2426261983 @default.
- W4308976884 hasRelatedWork W2794783788 @default.
- W4308976884 hasRelatedWork W4213271907 @default.
- W4308976884 hasRelatedWork W4214789906 @default.
- W4308976884 hasVolume "24" @default.
- W4308976884 isParatext "false" @default.
- W4308976884 isRetracted "false" @default.
- W4308976884 workType "article" @default.